[
  {
    "symbol": "NUVL",
    "price": 42.87,
    "beta": 0,
    "volAvg": 299930,
    "mktCap": 2435907525,
    "lastDiv": 0,
    "range": "12.0-45.25",
    "changes": 0.25,
    "companyName": "Nuvalent, Inc.",
    "currency": "USD",
    "cik": "0001861560",
    "isin": "US6707031075",
    "cusip": "670703107",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.nuvalent.com",
    "description": "Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.",
    "ceo": "Dr. James R. Porter Ph.D.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "70",
    "phone": "857 357 7000",
    "address": "One Broadway",
    "city": "Cambridge",
    "state": "MA",
    "zip": "02142",
    "dcfDiff": null,
    "dcf": 0,
    "image": "https://financialmodelingprep.com/image-stock/NUVL.png",
    "ipoDate": "2021-07-29",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]